---
title: 'Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in
  patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation:
  a study of the ALWP of the EBMT'
date: '2024-08-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39143183/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240815181506&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations have uncertain
  prognostic implications in AML. We investigate the impact IDH1 and IDH2 mutations
  in AML patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT)
  in first complete remission (CR1). In total, 1515 adult patients were included,
  15.91% (n = 241) carried IDH1 mutation (mIDH1), and 26.27% (n = 398) IDH2 mutation
  (mIDH2) and 57.82% (n = 876) had no-IDH mutation. NPM1 was frequently encountered
  with ...
disable_comments: true
---
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations have uncertain prognostic implications in AML. We investigate the impact IDH1 and IDH2 mutations in AML patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1). In total, 1515 adult patients were included, 15.91% (n = 241) carried IDH1 mutation (mIDH1), and 26.27% (n = 398) IDH2 mutation (mIDH2) and 57.82% (n = 876) had no-IDH mutation. NPM1 was frequently encountered with ...